Phase I Study of LBH589, A Novel Oral Deacetylase Inhibitor in Patients with Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
Description: 

The purpose of this study is to find out the effects of a drug called LBH589 when given to people with recurrent or refractory Hodgkin or Non-Hodgkin's lymphoma. The safety of this drug will also be studied. The participants physical state, changes in the size of the tumor, or state of Hodgkin or non-Hodgkin's Lymphoma, and laboratory findings taken while on-study will help the researchers decide if LBH589 is safe and effective.

Study Number: 

I 147408

Phase: 
I
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01032148

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.